Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases

被引：0

作者：

Nejabat, Mojgan ^{[1
]}

Hadizadeh, Farzin ^{[2
]}

Almahmeed, Wael ^{[3
]}

Sahebkar, Amirhossein ^{[4
,5
]}

机构：

[1] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran

[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran

[3] Cleveland Clin Abu Dhabi, Heart & Vasc Inst, Abu Dhabi, U Arab Emirates

[4] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India

[5] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran

来源：

DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期

关键词：

proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i); diabetes; cancer; cardiovascular; cerebrovascular; stroke; LDL-CHOLESTEROL; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PEOPLE; SAFETY; RISK; ERA;

D O I：

10.1016/j.drudis.2025.104316

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well as the management of diabetes, has been demonstrated. PCSK9i can also enhance outcomes and reduce cardiovascular (CV) events in individuals with a history of such events. In this review, we provide insights into the pharmacology, safety, and impact of PCSK9i. We highlight cutting-edge investigations, the development of innovative PCSK9i-based products, and a more comprehensive understanding of the potential effects of these drugs on cancer, diabetes, and CV and cerebrovascular diseases.

引用

页数：15

共 50 条

[41] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
Shapiro, Michael D.
Tavori, Hagai
Oleaga, Carlota
Miles, Joshua
Fazio, Sergio
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
[42] PCSK9 in metabolism and diseases
Ajoolabady, Amir
Pratico, Domenico
Mazidi, Mohsen
Davies, Ian G.
Lip, Gregory Y. H.
Seidah, Nabil
Libby, Peter
Kroemer, Guido
Ren, Jun
METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
[43] PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Handelsman, Yehuda
Lepor, Norman E.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (13):
[44] Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, Brian A.
Robinson, Jennifer G.
Brook, Robert D.
Catapano, Alberico L.
Chapman, M. John
Neff, David R.
Voros, Szilard
Giugliano, Robert P.
Smith, George Davey
Fazio, Sergio
Sabatine, Marc S.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2144 - 2153
[45] PLASMA PCSK9 AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES
El Khoury, Petra
Roussel, Ronan
Fumeron, Frederic
Velho, Gilberto
Jacob, Marie-Paule
Steg, Gabriel
Potier, L.
Ghaleb, Youmna
Elbitar, Sandy
Abifadel, Marianne
Boileau, Catherine
Marre, Michel
Varret, Mathilde
Hansel, Boris
ATHEROSCLEROSIS, 2017, 263 : E81 - E81
[46] PCSK9 inhibitors and diabetes risk: a question worth asking?
Sattar, Naveed
EUROPEAN HEART JOURNAL, 2016, 37 (39) : 2990 - 2992
[47] PCSK9 inhibitors and diabetes: Translational biology to clinical practice
Chilton, Robert J.
Oliveros, Rene
Gallegos, Kelly M.
Pham, Son
DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 451 - 453
[48] Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Peczek, Piotr
Lesniewski, Mateusz
Mazurek, Tomasz
Szarpak, Lukasz
Filipiak, Krzysztof J.
Gasecka, Aleksandra
LIFE-BASEL, 2021, 11 (06):
[49] PCSK9 inhibitors: signal for risk of neurocognitive effects
Reactions Weekly, 2017, 1638 (1) : 10 - 10
[50] The Anti-Thrombotic Effects of PCSK9 Inhibitors
Pec, Martin Jozef
Benko, Jakub
Jurica, Jakub
Pecova, Monika
Samec, Marek
Hurtova, Tatiana
Bolek, Tomas
Galajda, Peter
Pec, Martin
Samos, Matej
Mokan, Marian
PHARMACEUTICALS, 2023, 16 (09)

← 1 2 3 4 5 →